ProfileGDS5678 / 1453136_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 66% 69% 63% 65% 65% 66% 66% 66% 66% 66% 65% 67% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0625167
GSM967853U87-EV human glioblastoma xenograft - Control 23.9888566
GSM967854U87-EV human glioblastoma xenograft - Control 34.2806269
GSM967855U87-EV human glioblastoma xenograft - Control 43.7704263
GSM967856U87-EV human glioblastoma xenograft - Control 53.8916265
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9676765
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0393166
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9999966
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9530466
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9760866
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9728566
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8988465
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.098467
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.993366